The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The most important decision for community oncologists when managing newly diagnosed myeloma
In this video, Amrita Krishnan, MD, City of Hope, Duarte, CA, comments on the most important decision a community oncologist must make when managing a patient with newly diagnosed multiple myeloma (MM): selecting an optimal induction regimen. She highlights that the goal is to achieve a deep, durable first remission and recommends early involvement of a myeloma specialist. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think in myeloma we still believe sort of your first shot is your best shot. So the most important decision is to pick that induction regimen. And I think you have to incorporate all these things now. Risk status, patient frailty, patient goals. Think about sequencing now as we look to the use of CAR-T and bispecific antibodies in earlier lines of therapy. So I actually think that that initial decision is probably one of the most important decisions you make for a patient with myeloma...
I think in myeloma we still believe sort of your first shot is your best shot. So the most important decision is to pick that induction regimen. And I think you have to incorporate all these things now. Risk status, patient frailty, patient goals. Think about sequencing now as we look to the use of CAR-T and bispecific antibodies in earlier lines of therapy. So I actually think that that initial decision is probably one of the most important decisions you make for a patient with myeloma. I don’t disagree that myeloma has become an incredibly difficult disease because we keep moving the goalposts, right? So we changed our definition of high-risk. We keep getting new agents, and then we keep moving those new agents earlier into the course of therapy, and those agents have unique toxicities. So I think it really is consult with a myeloma specialist really out of the gate now. Don’t wait until the patient’s relapsed because they can sort of help guide that journey from the beginning. And really, again, because my talk is depth and duration of response, and that really is our goal now, a long, deep first remission for patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
